Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose initiation of amivantamab + lazertinib for EGFR-mutant advanced non-squamous non-small cell lung cancer
jRCTs031260638Phase 2Recruiting
- Sponsor
- Grant-in-Aid for Scientific Research
- Start
- Nov 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab and lazertinib in Non-small cell lung cancer (NS-NSCLC), sponsored by Grant-in-Aid for Scientific Research. Primary endpoint: Rate of treatment discontinuation due to adverse events at 4 months. Started Nov 2026; status: recruiting.
02
Drugs
amivantamablazertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs031260638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260638.